Moreover,a protective NFE2L2 promoter single nucleotide polymorphismhaplotype is associated with delayed onset and reduced PD risk.20 Considering OS and neuroinflammation roles inPD, NRF2 activation is considered a key pharmacological goal to reducePD advance. This evidence concerns the gene NFE2L2 and Parkinson disease.